نتائج البحث

LBA4 Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol

• Authors : O. Parikh; Mona Parmar; Silke Gillessen

Subjects: Oncology; medicine.medical_specialty; Coronavirus disease 2019 (COVID-19)

• Source: Annals of Oncology. 32:S1298

تفاصيل العنوان

Initial results from AQUARiUS, a prospective, observational, multi-centre phase IV study assessing patient-reported outcomes (PROs) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate plus prednisone (AAP) or enzalutamide (ENZ)

• Authors : Guillaume Ploussard; Redas Trepiakas; A. Reid

Subjects: Oncology; medicine.medical_specialty; business.industry

• Source: Annals of Oncology. 28:v287-v288

تفاصيل العنوان

Clinical Outcomes and Prognostic Factors in Nonmetastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors Therapy.

• Authors : Fujiwara, Ryo¹ (AUTHOR) ; Yamamoto, Shinya¹ (AUTHOR); Takemura, Kosuke¹ (AUTHOR)

• Source: Cancers. Aug2024, Vol. 16 Issue 15, p2659. 11p.

تفاصيل العنوان

Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa.

• Authors : Mita, Koji¹ (AUTHOR); Izumi, Kouji² (AUTHOR) ; Goriki, Akihiro^1,3 (AUTHOR)

• Source: Cancers. Feb2024, Vol. 16 Issue 3, p508. 12p.

تفاصيل العنوان

Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate.

• Authors : Fiala, Ondřej^1,2 ; Hošek, Petr²; Korunková, Hana¹

• Source: Cancer Medicine. Jan2024, Vol. 13 Issue 1, p1-10. 10p.

تفاصيل العنوان

Connecting Gene Variation to Treatment Outcomes in Metastatic Castration-Resistant Prostate Adenocarcinoma: Insights into Second-Generation Androgen Receptor Axis-Targeted Therapies.

• Authors : Vaz-Ferreira A; Oncology Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal.; Tavares V

Subjects: Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/genetics ; Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/drug therapy ; Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/pathology

• Source: International journal of molecular sciences [Int J Mol Sci] 2024 Sep 12; Vol. 25 (18). Date of Electronic Publication: 2024 Sep 12.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان

Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer.

• Authors : Tsujino, Takuya¹ (AUTHOR); Tokushige, Satoshi¹ (AUTHOR); Komura, Kazumasa¹ (AUTHOR)

• Source: Cancer Medicine. Oct2023, Vol. 12 Issue 19, p19414-19422. 9p.

تفاصيل العنوان

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide.

• Authors : Kawahara, Takashi¹ (AUTHOR); Saigusa, Yusuke² (AUTHOR); Yoneyama, Shuko¹ (AUTHOR)

• Source: BMC Cancer. 3/7/2023, Vol. 23 Issue 1, p1-8. 8p.

تفاصيل العنوان

Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC (ANZadapt)

• Authors : Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Anticancer Fund, Belgium; dr. Tom van der Hulle, Principal Investigator

• Source: ANZadapt: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer

تفاصيل العنوان

Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review.

• Authors : Shah, Yash B.¹ (AUTHOR) ; Shaver, Amy L.² (AUTHOR) ; Beiriger, Jacob¹ (AUTHOR)

• Source: Cancers. Aug2022, Vol. 14 Issue 15, p3773-3773. 16p.

تفاصيل العنوان